Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AirSculpt TechnologiesAIRS -0.24%74 Return-on-Tangible-Asset is -13.38% as of Mar. 2026. GuruFocus rates AIRS with a GF Score™ of 74/100 and a GF Value™ of $3.90 (Fairly Valued). The stock has 3 warning signs investors should review. Among 682 Healthcare Providers & Services companies, AirSculpt Technologies ranks worse than 77.27% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. AirSculpt Technologies's annualizedNet Income for the quarter that ended in Mar. 2026 was $-9.6 Mil. AirSculpt Technologies's average total tangible assets for the quarter that ended in Mar. 2026 was $71.7 Mil. Therefore, AirSculpt Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -13.38%.
The historical rank and industry rank for AirSculpt Technologies's Return-on-Tangible-Asset or its related term are showing as below:
AIRS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -22.43 Med: -9.06 Max: 24.57
Current: -11.5
During the past 7 years, AirSculpt Technologies's highest Return-on-Tangible-Asset was 24.57%. The lowest was -22.43%. And the median was -9.06%.
AIRS's Return-on-Tangible-Asset is ranked worse than 77.27% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 2.465
vs AIRS: -11.50
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
AirSculpt Technologies Return-on-Tangible-Asset Related Terms
AirSculpt Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for AirSculpt Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIRS vs AUNA, CCRN, SRTA: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, AirSculpt Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AirSculpt Technologies Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AirSculpt Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where AirSculpt Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -13.38% mean?
AirSculpt Technologies (AIRS) has a Return-on-Tangible-Asset of -13.38% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AirSculpt Technologies and its competitors. According to the industry distribution chart, AirSculpt Technologies ranks #527 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 77.3%.
Is AirSculpt Technologies' Return-on-Tangible-Asset too high?
AirSculpt Technologies' current Return-on-Tangible-Asset is -13.38%. Based on the distribution chart, AirSculpt Technologies ranks #527 out of 682 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, AirSculpt Technologies has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AirSculpt Technologies' Return-on-Tangible-Asset compare to AUNA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, AirSculpt Technologies ranks #527 out of 682 companies for Return-on-Tangible-Asset. This places AirSculpt Technologies in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.47, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AirSculpt Technologies and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AirSculpt Technologies's current Return-on-Tangible-Asset is -13.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AirSculpt Technologies stock overvalued right now?
Based on GuruFocus' analysis, AirSculpt Technologies (AIRS) is currently considered Fairly Valued. The stock's GF Value™ is $3.90, compared to a current price of $4.18 — trading 7.2% above its estimated fair value. The current Return-on-Tangible-Asset is -13.38%. AirSculpt Technologies' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For AirSculpt Technologies (AIRS), the current Return-on-Tangible-Asset is -13.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AirSculpt Technologies (AIRS) Overvalued in 2026?
Based on GuruFocus' analysis, AirSculpt Technologies stock appears to be overvalued.
The current stock price of $4.18 is trading 7.2% above its estimated GF Value™ of $3.90.
GuruFocus considers AirSculpt Technologies to be Fairly Valued.
Key valuation signals for AIRS:
Return-on-Tangible-Asset: -13.38%
GF Value™: $3.90 vs. price of $4.18 (7.2% above fair value)
No single metric tells the full story. See the AIRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
74GF Score
Get the complete analysis for AIRS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIRS has been successfully added to your 
